Michael Johnson

Michael Johnson is an experienced trial attorney. Michael’s practice focuses on patent litigation, counseling, and IP strategy. His litigation experience encompasses an array of technologies, including pharmaceuticals, biotechnology, medical devices, industrial chemicals, and consumer products, with particular focus on pharmaceuticals and biotechnology.

Michael has represented a variety of major life sciences companies in litigation matters in both the district courts as well as the PTAB. In addition to this experience, Michael has prevailed in several appeals following trials and preliminary injunction decisions.

Michael’s practice also includes client counseling on patent infringement, validity, and enforceability opinions and pre-litigation strategy, as well as intellectual property issues associated with transactional work including licensing and mergers.

Mr. Johnson started his career at Kenyon & Kenyon from 2000-2006, then worked at Willkie Farr & Gallagher LLP from 2006-2025, when he joined Gemini Law.

Mr. Johnson is Second Vice President of the New York Intellectual Property Law Association (NYIPLA).

U.S. Supreme Court Highlights Enablement and the Full Scope of Invention in Amgen Inc. v. Sanofi, Client Alert with H. Schneider (May 19, 2023)

U.S. Supreme Court Rules Patent Office Judge Oversight Unconstitutional but Offers New Fix to System, Client Alert with H. Schneider (June 23, 2021)

Trade Secret Updates: Litigation Developments and IP Waivers, Biosimilar Webinar Series with H. Schneider (June 9, 2021)

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, February 2021

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, November 2020

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2020

IP COVID-19 Update: Government Activities Impacting Pricing, Supply, and Research and Development in the Pharmaceutical and Medical Supply Industries, with H. Schneider (April 28, 2020)

U.S. Supreme Court Rules that Time-Bar Decisions Are Not Appealable in Patent Office Inter Partes Review Proceedings, Client Alert (April 23, 2020)

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, April 2020

IP COVID-19 Update: Procedural Restrictions at the Patent Office, PTAB, and Courts with Significant Patent Dockets, with H. Schneider (March 30, 2020)

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, January 2020

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2019

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2019

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, April 2019

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2018

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2018

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, January 2018

The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2017

PTAB Developments Involving CRISPR-Cas9 Gene Editing Technology, with H. Schneider, NYIPLA, The Report (April/May 2017)

Litigation Discovery Considerations from an In-house Counsel Perspective: Litigation Hold Memos, Spoliation and ESI, Moderator, NYIPLA

One Day Patent CLE Seminar, November 2016

The Rapidly Changing Patent Law Landscape: What Entrepreneurs, Investors, Inventors, Lawyers and Judges Need To Know, Speaker, NYIPLA and Rensselaer Polytechnic Institute, April 2015

Federal Circuit Review, Editor, monthly volumes from September 2008 to December 2012

Drug Approval Pathway Established for Biosimilar Drugs, Client Memorandum (April 1, 2010)